ALS Therapy Market Seen Increasing to Nearly $1.3B by 2029
Five-year Data for Genentech's Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
- After 5 years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not be expected to live past 2 years of age -- 96% of Evrysdi-treated children could swallo
Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024, Featuring Kojin Therapeutics, MitoImmune Therapeutics, Prothegen, PTC Therapeutics, Sumitomo and Tharimmune - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.The panorama of scienti
William Blair Maintains PTC Therapeutics(PTCT.US) With Buy Rating
William Blair analyst Sami Corwin maintains $PTC Therapeutics(PTCT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 43.9% and a total average return of 3.7% over th
Express News | EMA Says Chmp Has Restarted Evaluation of an Application to Renew Conditional Marketing Authorisation for Translarna (Ataluren)
PTC Therapeutics to Participate at Upcoming Investor Conference
WARREN, N.J., May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th Ann
Analysts' Opinions Are Mixed on These Healthcare Stocks: Insmed (INSM) and PTC Therapeutics (PTCT)
PTC Therapeutics: EMA To Review Sepiapterin MAA For PKU
Express News | PTC Therapeutics Inc -Submissions Are Planned in a Number of Additional Countries in 2024 Including Brazil and Japan
Express News | PTC Therapeutics Inc - Expects to Submit Sepiapterin Nda to FDA No Later Than Q3 of 2024
Express News | PTC Therapeutics Announces Validation of Sepiapterin European Maa
Insider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC Therapeutics Inc (PTCT)
PTC Therapeutics(PTCT.US) Director Sells US$764.8K in Common Stock
$PTC Therapeutics(PTCT.US)$ Director ZELDIS JEROME B sold 20,000 shares of common stock on May 22, 2024 at an average price of $38.24 for a total value of $764.8K.Source: Announcement What is statemen
Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing
Jerome B Zeldis, Director, on May 22, 2024, sold 20,000 shares in Ptc Therapeutics (PTCT) for $764,800. Following the Form 4 filing with the SEC, Zeldis has control over a total of 14,500 shares of th
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
RBC Capital Sticks to Its Hold Rating for PTC Therapeutics (PTCT)
Form 144 | PTC Therapeutics(PTCT.US) Director Proposes to Sell 764.77K in Common Stocks
SEC FILLINGS DISCLOSED/ May 22, $PTC Therapeutics(PTCT.US)$ Director ZELDIS JEROME B intends to sell 20,000 shares of its common stock on May 22, with a total market value of approximately $764.77K.
Analysts' Revenue Estimates For PTC Therapeutics, Inc. (NASDAQ:PTCT) Are Surging Higher
PTC Therapeutics, Inc. (NASDAQ:PTCT) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus estimated revenue
Hold Rating on PTC Therapeutics Amid Regulatory Uncertainty for Translarna
No Data